Yesterday was a historic day for NanoEcho. To our knowledge, this is the first time ever that the magnetomotive ultrasound method has been applied to human tissue. This was carried out on operated cancer tissue using NanoEcho’s first generation portable system at Sahlgrenska University Hospital in Gothenburg. Our system is designed to map, with high precision, the spread of cancer to the lymph nodes, an important marker of how far the cancer has progressed, even before surgery. Our clinical study is now underway at Sahlgrenska University Hospital.
It was a very educational day, and we appreciate the professional leadership of Senior Consultant and Professor, Eva Angene, and her team’s engaging approach. Everything has gone according to plan, and we have succeeded in identifying nanoparticles in the human tissue. As such, we have achieved our goal with the first patient. We now look forward to continuing the clinical study on operated tissue, and gathering knowledge and receiving guidance in readiness for the design and system development of the next system, adapted for commercialisation, says Linda Persson, CEO of NanoEcho.
One year ago, we submitted our joint ethics application for this clinical study. Due to the burden on healthcare from Covid, the start was delayed. It is exciting to finally be up and running, and I look forward to following the development of the study, says Professor and Senior Consultant, Eva Angenete, who is leading the study at Sahlgrenska University Hospital.
This press release was published in Swedish in 18 June 2021.
